Use of use of dimethyl fumarate for targeting autoimmunity in type 1 diabetes

富马酸二甲酯用于靶向 1 型糖尿病自身免疫的用途

基本信息

批准号：
10495266
负责人：
Allison Lorayne Bayer
金额：
$ 19.19万
依托单位：
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-24 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10495266
关键词：
Acute Adaptive Immune System Animal Model Animals Attenuated Autoantigens Autoimmune Diabetes Autoimmune Diseases Autoimmunity Award Beta Cell Cell physiology Cells Chronic Citric Acid Cycle Clinical Clinical Trials Data Development Diabetes Mellitus Diabetes prevention Diagnosis Disease Down-Regulation Esters Experimental Autoimmune Encephalomyelitis Experimental Models FDA approved Fumarates Fumaric acid Funding Future Goals Human Immune Immune response Immune system Immunotherapy Inbred NOD Mice Inflammatory Insulin Insulin-Dependent Diabetes Mellitus Investigation Lesion Life Lymphoid Cell Magnetic Resonance Imaging Mediating Metabolic Modeling Multiple Sclerosis Mus Myeloid Cells Natural Immunity Natural Killer Cells Oral Pancreas Pathogenesis Pathology Patients Pharmacotherapy Pilot Projects Prevention Process Property Regulatory T-Lymphocyte Relapse Relapsing-Remitting Multiple Sclerosis Reproducibility Research Risk Serum Structure of beta Cell of islet T-Lymphocyte T-Lymphocyte Subsets Testing Therapeutic Agents Time Treatment Efficacy Universities adaptive immune response adaptive immunity aerobic glycolysis blood glucose regulation cytokine drug action efficacy evaluation human subject immunoregulation improved innovation insulin dependent diabetes mellitus onset insulin secretion insulitis islet autoimmunity mouse model multiple sclerosis treatment novel strategies novel therapeutics optimal treatments pre-clinical preservation prevent response success translational potential

项目摘要

Title: Use of use of dimethyl fumarate for targeting autoimmunity in type 1 diabetes Abstract: Type 1 diabetes (T1D) in an autoimmune disease characterized by T-cell mediated destruction of insulin producing pancreatic beta-cells. Both innate and adaptive innate immunity are involved in this process. Immunotherapies so far have failed to achieve long-lasting effects on islet autoimmunity, so that prevention and reversal of T1D remain an unmet goal. Dimethyl fumarate (DMF) is an FDA-approved treatment for relapsing remitting multiple sclerosis. Multiple sclerosis data in both animal models and human subjects have shown that DMF targets innate and adaptive immune responses through several mechanisms, including the downregulation of aerobic glycolysis in activated myeloid and lymphoid cells (metabolic inhibition). Our preliminary data strongly suggests that DMF is a promising drug for the treatment of islet autoimmunity, and our long-term goal is to launch a clinical trial to test whether DMF preserves insulin secretion in T1D. As a pre-requisite, a clinical trial would have to be supported by preclinical data that demonstrate its efficacy in a disease-relevant model. Thus, the goal of this proposal is to conduct preclinical investigations in the NOD mouse model, a widely accepted model of T1D, to test whether DMF can antagonize autoimmunity at diabetes onset (diabetes reversal). This approach is the directly relevant to the clinical setting, where most new therapies being considered for islet autoimmunity are first tested in clinical trials of patients with recent T1D onset. Therefore, our specific aims are: 1) To fully test the hypothesis that DMF therapy reverses diabetes and obtain definitive reproducible efficacy data in NOD mice; 2) To characterize the effects and mechanisms of action of DMF therapy by studying immune subsets, autoantigen specific responses, pancreas pathology and β-cell function. This study is significant since DMF has not been tested in T1D and yet is appears to possess many desirable properties. The proposed project is also innovative since represents a new approach in treating the disease through a mechanism of action which includes metabolic inhibition. 0

标题：富马酸二甲酯用于靶向 1 型糖尿病自身免疫的用途摘要： 1 型糖尿病（T1D）是一种由 T 细胞介导的自身免疫性疾病。破坏产生胰岛素的胰腺β细胞先天性和适应性先天免疫。迄今为止，参与这一过程的免疫疗法未能取得持久的效果。胰岛自身免疫，因此预防和逆转 T1D 仍然是一个未实现的目标。富马酸盐（DMF）是 FDA 批准的一种治疗复发缓解型多发性硬化症的药物。动物模型和人类受试者的硬化数据表明，DMF 靶向先天性和通过多种机制进行适应性免疫反应，包括下调活化的骨髓细胞和淋巴细胞中的有氧糖酵解（代谢抑制）。数据强烈表明 DMF 是一种有前途的治疗胰岛自身免疫的药物，并且我们的长期目标是开展一项临床试验，测试 DMF 是否能保持胰岛素分泌 T1D。作为先决条件，临床试验必须得到临床前数据的支持。因此，该提案的目标是在疾病相关模型中证明其功效。 NOD 小鼠模型（一种广泛接受的 T1D 模型）的临床前研究，以测试 DMF 是否可以在糖尿病发作时拮抗自身免疫（糖尿病逆转）。与临床环境直接相关，大多数新疗法都被考虑用于胰岛自身免疫首先在最近发病的 T1D 患者的临床试验中进行测试。具体目标是： 1) 充分检验 DMF 疗法逆转糖尿病的假设并获得 NOD 小鼠中明确的可重复功效数据；2) 表征效果和机制通过研究免疫亚群、自身抗原特异性反应、胰腺来了解 DMF 治疗的作用由于 DMF 尚未在 T1D 和 β 细胞功能中进行测试，因此这项研究具有重要意义。然而，拟议的项目似乎具有许多理想的特性。因为代表了一种通过作用机制治疗该疾病的新方法，包括代谢抑制。 0